ETNA
Desconocido
STriTuVaD: In Silico Trial for Tuberculosis Vaccine Development
ETNA BIOTECH SRL
tramitó un
H2020
H2020-SC1-2016-2017
Tuberculosis (TB) one of the world’s deadliest diseases: one third of the world’s population, mostly in developing countries, is infected wi...
2017-11-13 - 2023-01-31 | Financiado
2017-11-13 - 2023-01-31 | Financiado
MULEVACLIN: Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis
ETNA BIOTECH SRL
tramitó un
FP7
The World Health Organisation in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the b...
Financiado
Financiado
EDUFLUVAC: Combinatorial immunization strategy to educate the immune system towards cross recognition and cover...
ETNA BIOTECH SRL
participó en un
FP7
As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, t...
Financiado
Financiado
* No se disponen de datos de la empresa actual.